BioStock: Curasight hope to build upon strong momentum

In many ways, the second quarter was pivotal for the Danish biotech company Curasight. The company secured its first partnership deal and could also present further promising results in the main indication, brain cancer. BioStock contacted CEO Ulrich Krasilnikoff to learn more.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/08/curasight-hope-to-build-upon-strong-momentum/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se